Literature DB >> 2142142

Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity.

R Tsuboi1, D B Rifkin.   

Abstract

Three human tumor cell lines, Bowes' melanoma, HT1080 and Osmond cells, were characterized for their ability to invade the amniotic membrane and their production of plasminogen activator. Bowes' melanoma cells, which release large amounts of tissue plasminogen activator (tPA), were poorly invasive on the amniotic membrane. The addition of plasmin inhibitors, anti-tPA antibody or tissue inhibitor of metalloproteinase (TIMP) to the amnion assay enhanced invasiveness. The depletion of plasminogen from the growth medium also enhanced the degree of invasiveness. Similarly, HT1080 cells, which produce high levels of urokinase-type plasminogen activator (uPA), were poorly invasive under standard conditions but invasion was enhanced by plasmin inhibitors or anti-uPA antibodies. Conversely, Osmond cells, which produce low levels of uPA, were very invasive on the amniotic membrane. Invasion by these cells was blocked by the addition of plasmin inhibitors or anti-uPA antibodies to the amnion assay. These results suggest that invasion requires only a minimum level of PA activity and that, as PA production exceeds this optimal level, the degree of invasion decreases. We propose that high levels of plasmin, generated by the tPA or uPA secreted by the cells, may cause uncontrolled matrix degradation and interrupt the interaction of cells and matrix in the early stages of invasion. The inhibition of excessive plasmin activity may stabilize and increase cell matrix contacts and result in an enhancement of invasion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2142142     DOI: 10.1002/ijc.2910460112

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model.

Authors:  M R Gyetko; G H Chen; R A McDonald; R Goodman; G B Huffnagle; C C Wilkinson; J A Fuller; G B Toews
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

2.  Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner.

Authors:  D H Nguyen; A D Catling; D J Webb; M Sankovic; L A Walker; A V Somlyo; M J Weber; S L Gonias
Journal:  J Cell Biol       Date:  1999-07-12       Impact factor: 10.539

3.  Development of decellularized amniotic membrane as a bioscaffold for bone marrow-derived mesenchymal stem cells: ultrastructural study.

Authors:  Radwa Ayman Salah; Ihab K Mohamed; Nagwa El-Badri
Journal:  J Mol Histol       Date:  2018-03-22       Impact factor: 2.611

Review 4.  Current and future strategies to block tumor angiogenesis, invasion, and metastasis.

Authors:  P J Effert; G Gastl; T Strohmeyer
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

5.  Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.

Authors:  C Kunz; S Pebler; J Otte; D von der Ahe
Journal:  Nucleic Acids Res       Date:  1995-09-25       Impact factor: 16.971

6.  Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network.

Authors:  M Jeffers; S Rong; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

7.  Gelatinase A activity directly modulates melanoma cell adhesion and spreading.

Authors:  J M Ray; W G Stetler-Stevenson
Journal:  EMBO J       Date:  1995-03-01       Impact factor: 11.598

8.  Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth.

Authors:  D J Webb; K S Thomas; S L Gonias
Journal:  J Cell Biol       Date:  2001-02-19       Impact factor: 10.539

9.  Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.

Authors:  D Foucré; C Bouchet; K Hacène; N Pourreau-Schneider; A Gentile; P M Martin; A Desplaces; J Oglobine
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.